XRP Breaks Resistance: Analysts Eye Bullish Altcoin Momentum — Kaanch Network Presale Opens at $0.16 as Investors Hunt the Next 10x Token
DUBAI, United Arab Emirates, May 10, 2025 (GLOBE NEWSWIRE) — With XRP breaking through key resistance and trading above trend lines for the first time in months, crypto analysts are calling for a renewed bull phase in select altcoins. But beyond XRP, early-stage investors are already turning their attention to the next high-potential project. One name rising in these circles: Kaanch Network , currently priced at $0.16 in Stage 5 of its presale.
The XRP rally has re-energized market sentiment, reminding investors of the classic altcoin pattern — early-stage utility, months of quiet accumulation, and then a breakout triggered by real developments. Analysts note that Kaanch Network appears to follow a similar trajectory — but with a new focus: Web3 governance and on-chain infrastructure.
The XRP Pattern Repeating? Early ecosystem utility
Undervalued market cap
Overlooked for months
Sudden breakout after tech or market catalysts
While XRP transformed cross-border finance, Kaanch is applying that same breakout framework to DAO infrastructure and decentralized governance.
What Is Kaanch Network?
Founded in 2023 by Rahul Kumar and Ved Singh, Kaanch Network is a blockchain protocol designed for speed, modularity, and real-time coordination. It offers tools for staking, DAO creation, and no-code governance modules — enabling small teams and startups to launch full-stack Web3 projects without technical barriers.
Already operational, the Kaanch platform is seeing growing adoption among builders looking for customizable governance infrastructure.
Why Investors Are Comparing Kaanch to Early XRP Token is already live with working utility
DAO and staking modules available to users
No-code setup ideal for rapid Web3 launches
Presale currently open at $0.16 — with next stage priced higher
Kaanch empowers creators to launch decentralized ecosystems without relying on developers — providing a real solution in a market where governance is still fragmented.
Could Kaanch Follow a Similar Growth Path?
With the presale still open, early adopters are positioning for what could mirror XRP's early breakout — only now in the infrastructure layer of Web3: Low entry point
Real-world utility in governance and staking
Rising demand for DAO infrastructure
Upcoming exchange listings following presale close
Investors looking to catch the next wave beyond XRP are increasingly pointing toward tokens like $KNCH — with functionality, a live product, and ecosystem potential.
FAQ
What is the Kaanch Network?
Kaanch Network is a governance-focused blockchain platform enabling tokenized ecosystems, DAO deployment, and real-time coordination. It supports developers and non-developers alike with fast, interoperable infrastructure and no-code tools.
Is Kaanch Network Legitimate?
Yes. The platform is live, with audited smart contracts and a publicly known team. Its tools are already being used by early adopters across Web3, with growing traction in the DAO and DeFi space.
Where can I buy $KNCH?
Presale access is currently open at: https://presale.kaanch.com
Contact:Ved Singh
[email protected]
Disclaimer: This is a paid post and is provided by Kaanch Network . The statements, views, and opinions expressed in this content are solely those of the content provider and do not necessarily reflect the views of this media platform or its publisher. We do not endorse, verify, or guarantee the accuracy, completeness, or reliability of any information presented. We do not guarantee any claims, statements, or promises made in this article. This content is for informational purposes only and should not be considered financial, investment, or trading advice. Investing in crypto and mining-related opportunities involves significant risks, including the potential loss of capital. It is possible to lose all your capital. These products may not be suitable for everyone, and you should ensure that you understand the risks involved. Seek independent advice if necessary. Speculate only with funds that you can afford to lose. Readers are strongly encouraged to conduct their own research and consult with a qualified financial advisor before making any investment decisions. However, due to the inherently speculative nature of the blockchain sector—including cryptocurrency, NFTs, and mining—complete accuracy cannot always be guaranteed. Neither the media platform nor the publisher shall be held responsible for any fraudulent activities, misrepresentations, or financial losses arising from the content of this press release. In the event of any legal claims or charges against this article, we accept no liability or responsibility. Globenewswire does not endorse any content on this page.
Legal Disclaimer: This media platform provides the content of this article on an 'as-is' basis, without any warranties or representations of any kind, express or implied. We assume no responsibility for any inaccuracies, errors, or omissions. We do not assume any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information presented herein. Any concerns, complaints, or copyright issues related to this article should be directed to the content provider mentioned above.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a968ec58-dbbe-4acf-98c6-45d40ef38c6b
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
Aptose Reports Early Data Demonstrating Tuspetinib Improves Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML in Phase 1/2 TUSCANY Trial
Addition of Tuspetinib (TUS) to Venetoclax (VEN) and Azacitidine (AZA) is being developed as safe and mutation agnostic frontline therapy for AML Addition of TUS to VEN+AZA improves response rates; 100% CR/CRh at 80 mg and 120 mg Addition of TUS to VEN+AZA improves MRD-negativity rates; 78% among responders 100% CR/CRh in FLT3 wildtype AML, representing 70% of AML population 100% CR/CRh and MRD-negativity rates in TP53, RAS and FLT3-ITD mutated AML Broad spectrum activity and excellent safety profile continue at 120 mg dose to date SAN DIEGO and TORONTO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ('Aptose' or the 'Company') (OTC: APTOF, TSX: APS), a clinical-stage precision oncology company developing the tuspetinib (TUS)-based triple drug frontline therapy to treat patients with newly diagnosed AML, today provided a data update from the Phase 1/2 TUSCANY trial in newly diagnosed AML. The trial was initiated in December 2024, and the growing body of positive data includes the recently completed third cohort of 120 mg TUS in the TUS+VEN+AZA triplet therapy. Data to date from ten (10) patients across all three cohorts, 40 mg, 80 mg or 120 mg TUS dose in TUS+VEN+AZA, support the use of TUS with standard of care treatment across all AML populations, including those carrying mutations that are the most difficult to treat and those with mutated and unmutated (wildtype) FLT3 genes. The TUS+VEN+AZA triplet is being developed as a safe and well-tolerated mutation agnostic frontline therapy to treat large, mutationally diverse populations of newly diagnosed AML patients who are ineligible to receive induction chemotherapy. At the 120 mg TUS dose level in combination with VEN+AZA, as with the prior reported 40 mg and 80 mg TUS dose cohorts, no significant safety concerns or dose limiting toxicities (DLTs) have been observed in the TUSCANY trial, including no prolonged myelosuppression in Cycle 1 of subjects in remission, no reports of drug-related QTc prolongation or differentiation syndrome (DS), and no treatment-related deaths. Nine out of ten dosed patients remain on study across all dose cohorts and enrollment is being advanced to the 160 mg TUS dose level following the Cohort Safety Review Committee (CSRC) meeting. 'We already have data from three different TUS dose levels in the TUSCANY trial, and the data continue to strengthen at higher doses of TUS and over time. We are building a strong case for TUS+VEN+AZA as a triplet frontline therapy of choice to address a broad AML population, including subgroups with the most adverse of mutations,' said William G. Rice, Ph.D., Chairman, President and Chief Executive Officer of Aptose. Data highlights: Comparison of CR/CRh1 Response rates2-5: VEN+AZA2 TUS+VEN+AZA All subjects 65% 90% (9/10) NPM1-mutant 67% 100% (2/2) FLT3-ITD 61% 100% (2/2) TP53-mutant 52% 100% (2/2) Comparison of MRD-negativity6 rates among All Subjects and among CR/CRh Responders3: VEN+AZA2,3 TUS+VEN+AZA Among All Subjects 23.4% 70% (7/10) Among CR/CRh Responders 40.9% 78% (7/9) Comparison of MRD-negativity rates among more difficult-to-treat Patient Subpopulations defined as Lower Benefit (TP53-mutated) and Intermediate Benefit (FLT3-ITD or RAS-mutated) relative to VEN+AZA5: VEN+AZA3,5 TUS+VEN+AZA Intermediate Benefit 27.9% 100% (3/3) Lower Benefit 14.5% 100% (2/2) TUS+VEN+AZA - CR/CRh and MRD-negativity rates among Subjects with Adverse Mutations: TP53, FLT3-ITD, RAS mutations: Achieved CR/CRh and MRD-negativity 100% (5/5) 'As illustrated in the data highlights, the addition of TUS to VEN+AZA appears to boost response rates and MRD-negativity while maintaining favorable safety and tolerability,' said Rafael Bejar, M.D., Ph.D., Chief Medical Officer of Aptose, 'and the 100% CR/CRh and 100% MRD-negativity rates among the five biallelic TP53-mutant, FLT3-ITD, and RAS-mutant AML cases are exciting to see, as this can correlate with longer overall survival. We have observed a trend towards achieving CRs more quickly at the higher dose levels, so we are keen to see the activity as we advance into the 160 mg TUS dose cohort.' Key messages: Addition of TUS to VEN+AZA demonstrates excellent CR/CRh rates 100% CR/CRh among all subjects treated at 80 mg and 120 mg TUS dose levels Appear to be achieving CR earlier with 120 mg TUS than with 40 mg or 80 mg Addition of TUS to VEN+AZA demonstrates excellent MRD-negativity rates MRD-negativity in 7 of 9 (78%) already achieved in patients who responded to therapy Expect patient survival to be extended with continued long-term treatment Excellent safety and well tolerated with no dose-limiting toxicities (No DLT) at completed dose levels Broad-spectrum activity including patients with adverse TP53, RAS and FLT3-ITD mutations No loss of MRD-negativity observed to date, including in one patient with over 7 months of follow up MRD-negativity and remissions continue to mature over time on therapy No relapses reported to date and no treatment related deaths The only non-responder was a patient at the initial TUS dose level (40 mg) that did not achieve TUS exposures previously associated with response Additional data are included in the new Aptose corporate presentation here. TUSCANY: TUS+VEN+AZA Triplet Phase 1/2 Study The tuspetinib-based TUS+VEN+AZA triplet therapy is being advanced in the TUSCANY Phase 1/2 trial with the goal of creating an improved frontline therapy for newly diagnosed AML patients that is active across diverse AML populations, durable, and well tolerated. The TUSCANY triplet Phase 1/2 study, being conducted at 10 leading U.S. clinical sites by elite clinical investigators, is designed to test various doses and schedules of TUS in combination with standard dosing of AZA and VEN for patients with AML who are ineligible to receive induction chemotherapy. A convenient, once daily oral agent, TUS is being administered in 28-day cycles. Multiple U.S. sites are enrolling in the TUSCANY trial with anticipated enrollment of 18-24 patients by late 2025. Data will be released as it becomes available. More information on the TUSCANY Phase 1/2 study can be found on (here). About Aptose Aptose Biosciences is a clinical-stage biotechnology company committed to developing precision medicines addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's lead clinical-stage, oral kinase inhibitor tuspetinib (TUS) has demonstrated activity as a monotherapy and in combination therapy in patients with relapsed or refractory acute myeloid leukemia (AML) and is being developed as a frontline triplet therapy in newly diagnosed AML. For more information, please visit Forward Looking Statements This press release may contain forward-looking statements within the meaning of Canadian and U.S. securities laws, including, but not limited to, statements relating to the therapeutic potential and safety profile of tuspetinib (including the triplet therapy) and its clinical development, the anticipated enrollment rate in the TUSCANY trial and the timing thereof, as well as statements relating to the Company's plans, objectives, expectations and intentions and other statements including words such as 'continue', 'expect', 'intend', 'will', 'should', 'would', 'may', and other similar expressions. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements described in this press release. Such factors could include, among others: our ability to obtain the capital required for research and operations and to continue as a going concern; the inherent risks in early stage drug development including demonstrating efficacy; development time/cost and the regulatory approval process; the progress of our clinical trials; our ability to find and enter into agreements with potential partners; our ability to attract and retain key personnel; changing market conditions; inability of new manufacturers to produce acceptable batches of GMP in sufficient quantities; unexpected manufacturing defects; and other risks detailed from time-to-time in our ongoing quarterly filings, annual information forms, annual reports and annual filings with Canadian securities regulators and the United States Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled 'Risk Factors' in our filings with Canadian securities regulators and the United States Securities and Exchange Commission underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. We cannot assure you that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein. For further information, please contact: Aptose Biosciences PietropaoloCorporate Communications & Investor Relations201-923-2049spietropaolo@ 1 Complete Response / Complete Response with Partial Hematological Recovery2 DiNardo et al. New England Journal of Medicine, August 2020; Volume 383(7):617-629.3 Pratz et al. Journal of Clinical Oncology, December 2021; Volume 40 (8):855-865.4 Othman et. al. Blood Neoplasia; September 2024; Volume 1 (3):1-11.5 Döhner et. al. Blood. 2024 November 21;144(21):2211-2222.6 MRD-negative indicates that the amount of Measurable Residual Disease, as assessed by central flow cytometry, is such that the proportion of leukemic cells in a bone marrow sample falls below <0.1%Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
33 minutes ago
- Yahoo
The Apache Software Foundation Announces Apache Ozone 2.0.0
First object store to support operational databases, now with major usability and compatibility enhancements Wilmington, DE, Aug. 19, 2025 (GLOBE NEWSWIRE) -- The Apache Software Foundation (ASF), the global home of open source software the world relies on, today announced Apache Ozone 2.0.0, a major milestone for the cloud-native distributed object store built for big data, analytics, and AI workloads. "Apache Ozone 2.0.0 represents years of community collaboration and production lessons from large-scale deployments,' said Sammi Chen, Apache Ozone PMC Chair and Principal Engineer at Cloudera. 'We're seeing growing adoption of Ozone in production, and this release brings the stability, performance, and ecosystem integration users have asked for." Ozone 2.0.0 responds to growing demand from organizations building AI and analytics platforms that require scalable, fault-tolerant, and cost-efficient storage—without giving up on performance or operational ease. Key Highlights of Apache Ozone 2.0.0: Operational Database Support: Apache Ozone is the first object store to support Apache HBase, enabling low-latency read/write workloads alongside traditional object storage. Atomic Key Operations: Support for atomic key overwrite and key replacement improves consistency for applications running concurrently. Modernized Recon UI: The Ozone Recon monitoring interface has been redesigned for clarity, with better metrics and navigation to support administrators. Expanded Platform Support: Now compatible with JDK 17 and JDK 21, and builds natively on ARM64, enabling broader deployment options. Improved Snapshots: Snapshot operations are more robust and efficient, particularly in large-scale environments with frequent replication or churn. Day-2 Operations: SCM decommissioning is now supported, making it easier to safely remove or rotate hardware as part of lifecycle management. With version 2.0.0, Apache Ozone continues its evolution from an object store for Apache Hadoop to a modern, cloud-native storage platform designed for AI, data lakehouses, and hybrid cloud use cases. For more information on Apache Ozone 2.0.0 and to get started, visit Additional Resources: Download: Documentation: Blog: GitHub: Follow on X/Twitter: @ApacheOzone About The Apache Software Foundation (ASF)The Apache Software Foundation (ASF) is the global home for open source software, powering some of the world's most ubiquitous software projects including Apache Airflow, Apache Camel, Apache Cassandra, Apache Groovy, Apache HTTP Server, and Apache Kafka. Established in 1999, the ASF is at the forefront of open source innovation, setting industry standards to advance software for the public good. Learn more at ASF's annual Community Over Code event is where open source technologists convene to share best practices and use cases, forge critical relationships, and learn about advancements in their field. © The Apache Software Foundation. 'Apache' is a registered trademark or trademark of the Apache Software Foundation in the United States and/or other countries. All other brands and trademarks are the property of their respective Brian Proffitt press@ Vice President, Marketing & Publicity The Apache Software FoundationError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Bitcoin, XRP Longs Get Rekt and Charts Flash Warning Signs: Analysis
The crypto market is painting the charts red today, with a sweeping correction hitting pretty much every major asset as traders take profits. Bitcoin dropped 2% to test the $115K mark, XRP slipped below that battle-tested $3 price point, and Ethereum dipped 3.5% to under $4,400. The selloff reflects a classic cocktail of profit-taking, leverage unwinding, and mounting macro uncertainty ahead of Federal Reserve Chair Jerome Powell's critical Jackson Hole speech this week. The market carnage has been particularly brutal for leveraged traders. Bitcoin alone saw over $120 million in liquidations in the past 24 hours driven by excessive leverage. XRP longs got rekt to the tune of $20 million, and Ethereum long positions got hosed for over $190 million. All in all, the crypto market as whole experienced over $500 million in forced selling with long positions getting crushed at a 5:1 ratio to shorts, according to data from CoinGlass. This liquidation cascade comes after Bitcoin's remarkable run to $124,500 last week, suggesting overheated positioning needed a reset. What do the charts say happens next? Let's dive in: Bitcoin (BTC) price: Testing critical support Bitcoin opened today at $117,465 before sliding to a low of $114,706 then bouncing to its current price just above $116,000. The flagship cryptocurrency's relatively modest drop compared to altcoins suggests institutional support remains. But technical indicators are starting to look not so cute if you're a Bitcoin permabull. You wouldn't know it, though, by gauging general sentiment, including on Myriad—a prediction market created by Decrypt's parent company Dastan. At the moment, Myriad traders still give Bitcoin a 60% chance to hit a new all-time of $125,000 before dipping back down to $105K. But the optimism is waning: Just days ago, the odds were at 90% on this market on Myriad. That makes sense, given what the charts are showing: a major cooldown with bears retaking some ground. Bitcoin's Relative Strength Index, or RSI, is at 47, sitting almost perfectly in neutral territory—neither oversold nor overbought. RSI is like a thermometer for the market, measuring how hot or cold things are on a scale from 0 to 100. Right around 50 suggests the market is in equilibrium. For traders, this means Bitcoin isn't stretched in either direction, suggesting room for movement both up and down. This neutral reading after a decline often precedes consolidation before the next directional move. This often makes it easier for day traders to determine zones of support and resistance, then open positions and play with the bounces before a decisive move in either direction. Right now, traders would likely point to the $116K-$120K zone as a good reference point to set stop loss and take profit orders in leverage markets. Bitcoin's Average Directional Index, or ADX, is at 21, which tells an important story about trend strength. ADX measures how strong a price trend is on a scale from 0 to 100, where readings below 25 indicate no clear trend. At 21, Bitcoin is in a "trendless" state, which usually means choppy, range-bound trading to come. Traders interpret this as a market searching for direction—not ideal for trend-following strategies but potentially profitable for range traders who buy support and sell resistance. This further validates the idea of traders potentially playing with the price bounces in short timeframes until markets decide whether BTC moons or dips. But if you're looking for bullish signals, then look no further than the exponential moving averages for BTC. These averages, or EMAs, give traders a better idea of where price supports may be by taking the average price of an asset over a set period of time. At the moment, Bitcoin's 50-day EMA, the shorter average, is above the 200-day EMA, the longer average. This typically signals longer-term bullish momentum. However, with price action now testing these averages, they'll act as dynamic support levels. The Squeeze Momentum Indicator showing "on" status is particularly significant. This indicator identifies when volatility compresses before explosive moves, suggesting a big move is brewing but prices are failing to gather enough strength to break either the buy or sell walls. Key Levels: Immediate support: $114,700 (today's low) Strong support: $110,000 (psychological level) Immediate resistance: $120,000 (horizontal channel resistance) Strong resistance: $124,500 (all-time high) Ethereum (ETH) price: Strong trend despite correction While Bitcoin's dip may have been modest, Ethereum's drop was notably harsh. ETH opened at $4,475.15 and tumbled to a low of $4,279.45 before settling at $4,327.52, a painful 3.30% decline. And yet, despite the selloff, ETH's technical structure on the charts remains surprisingly robust. What's more, the correction hasn't dampened the mood among traders on prediction markets—at least, not entirely. Myriad users still expect to see a new Ethereum ATH by the end of 2025. But those odds have sunk relative to last week's high, dropping from 93% to just 77% today. In other words, Myriad predictors remain bullish, but not nearly with the same conviction. Again, this tracks with what the ETH charts are showing. Ethereum's RSI is at 61, which is a welcome sight for ETH bulls after a 3% drop in price. RSI above 50 typically indicates buying pressure outweighs selling, and readings between 60-70 suggest strong momentum without being overbought. This tells traders that despite today's decline, the underlying buying interest remains intact. It's like a strong athlete taking a breather—tired but not exhausted. The ADX at 46 is exceptionally strong and deserves attention. When ADX reads above 40, it indicates an extremely powerful trend. This is "trending strongly" territory where momentum traders thrive. Despite today's pullback, this high ADX suggests the broader uptrend remains intact. It would be very easy for traders to interpret this data as a healthy correction within a bull market rather than a reversal. The 50-day EMA sitting well above the 200-day EMA creates another bullish buffer zone. This wide gap acts as multiple layers of support during corrections. Currently, ETH would need to fall significantly further to threaten this bullish structure. The Squeeze Momentum showing "off" status indicates the recent volatility expansion has played out, suggesting a period of consolidation ahead. Key Levels: Immediate support: $4,163 (weak support) Strong support: $3,800 (break below the psychological $4,000 level and previously tested area) Immediate resistance: $4,775 (all-time high) Strong resistance: $5,000 (psychological round level after price discovery) XRP price: Bears take control Meanwhile, XRP holders continue to be taken on a wild ride. The Ripple-linked token started the day at $3.0895 before bears drove it down to $2.9424, breaking below the psychological significant price point of $3.00. At the moment, it's trading slightly above that mark. But the token's inability to hold above the $3 level, or go higher, signals short-term weakness. Prediction market traders are also expressing caution after the recent run-up and subsequent dip for XRP. On Myriad, expectations are split almost evenly between those who think the coin will maintain its bullish momentum and touch $4 before a dip and those who expect a stronger correction to come. Myriad users currently place the odds at 56% for the XRP 'moon' scenario, but that's also down significantly from last week, when predictors placed those odds at 75%. The charts, once again, support this weakened bullish sentiment. XRP's RSI is at 47, which places the token in slightly bearish territory—below the neutral 50 line but not yet oversold. This reading suggests mild selling pressure without panic. For traders, RSI between 40-50 often represents a "decision zone" where the asset could either bounce from mild oversold conditions or continue lower if selling intensifies. It's essentially a coin flip without other confirming signals. The ADX at 24 is just below the crucial 25 threshold that confirms trend establishment. This "almost trending" reading creates uncertainty. The market is building directional momentum but hasn't quite committed. Traders often wait for ADX to decisively break above 25 before taking trend-following positions, making current levels a watch-and-wait scenario. Like with ETH, the EMAs should lift the spirits of the XRP bulls—but only so much. With the 50-day EMA above the 200-day EMA, the longer-term structure remains bullish. But XRP's current price proximity to these averages makes them critical battlegrounds. The Squeeze Momentum indicator's "on" status adds intrigue: This compression indicator suggests volatility is coiling like a spring, ready to release in either direction. That likely signals caution for traders, since the token has already experienced an explosive upward price move not too long ago. It wouldn't be so crazy, then, to prepare for a dip now that things are headed in the other direction. Key Levels: Immediate support: $2.94 (today's low) Strong support: $2.80 (psychological level) Immediate resistance: $3.09 (opening level) Strong resistance: $3.40 (recent resistance zone) The views and opinions expressed by the author are for informational purposes only and do not constitute financial, investment, or other advice.
